Search
Phenobarbital
go.drugbank.com/drugs/DB01174ApprovedInvestigationalIt promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnMore specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene. … Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationaland mortality in hospitalized patients. … Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections
Mixtures: Zosyn in Galaxy Containers, Zosyn in Galaxy ContainersCupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Synonyms: copper(II) chlorideMixtures: Tracel Injektionslösung in einer Fertigspritze, Trace Elements Solution InjZolpidem
go.drugbank.com/drugs/DB00425ApprovedInvestigationalThis drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. … It is aimed for use in patients with difficulties initiating sleep.
Synonyms: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamideChromic chloride
go.drugbank.com/drugs/DB09129ApprovedChromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: M T E 4 Concentrate Inj, Trace Elements Solution InjCategories: Compounds used in a research, industrial, or household settingTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy
Choline C 11
go.drugbank.com/drugs/DB09277Approved[A32041] It was developed by MCPRF and FDA first approved in September 2012. … Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalAfterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. … In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Synonyms: 2-chloro-N-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-